Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007068
Filing Date
2025-05-09
Accepted
2025-05-09 07:40:19
Documents
73
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q qure-20250331x10q.htm   iXBRL 10-Q 1878799
2 EX-10.1 qure-20250331xex10d1.htm EX-10.1 316220
3 EX-10.2 qure-20250331xex10d2.htm EX-10.2 96102
4 EX-31.1 qure-20250331xex31d1.htm EX-31.1 14948
5 EX-31.2 qure-20250331xex31d2.htm EX-31.2 14957
6 EX-32.1 qure-20250331xex32d1.htm EX-32.1 14638
  Complete submission text file 0001558370-25-007068.txt   8185132

Data Files

Seq Description Document Type Size
7 EX-101.SCH qure-20250331.xsd EX-101.SCH 52105
8 EX-101.CAL qure-20250331_cal.xml EX-101.CAL 57149
9 EX-101.DEF qure-20250331_def.xml EX-101.DEF 266175
10 EX-101.LAB qure-20250331_lab.xml EX-101.LAB 475936
11 EX-101.PRE qure-20250331_pre.xml EX-101.PRE 372222
76 EXTRACTED XBRL INSTANCE DOCUMENT qure-20250331x10q_htm.xml XML 1193061
Mailing Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP
Business Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP 1-339-970-7000
uniQure N.V. (Filer) CIK: 0001590560 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36294 | Film No.: 25928405
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)